|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Maryland Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MarylandLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Trophogen, Inc
| | | Phone: | (301) 838-1935 | Fax: | (301) 762-6287 | Year Established: | 2001 | Main Contact: | Bruce D. Weintraub, MD, President, CEO & Co-Founder | | Other Contacts: | Mariusz W. Szkudlinski, MD, PhD, Executive VP, CSO & Co-Founder
| |
| Company Description | Trophogen is a U.S.-based biotechnology company with Series A funding from Toucan Capital, focusing on the development of human and bovine high affinity glycoprotein hormone and related growth factor superagonist analogs for human infertility, animal superovulation, wound healing as well as targeted imaging and therapy of thyroid, ovarian, breast, prostate and testicular cancers, in certain cases employing novel superagonist-targeted nanoparticles. Trophogen's lead human product is a long-acting human FSH superagonist for a multibillion dollar human infertility market, which is providing a long awaited solution for “poor responders” and a large number of patients initially disqualified from IVF. Its lead animal product, a long-acting bovine FSH superagonist, has been licensed to Zoetis, and the company also has developed various additional long-acting equine and bovine CG superagonist for large markets in other aspects of bovine porcine & other livestock reproduction and various VEGF and PDGF analogs for wound healing in animals. | |
|
|
|
|
|